Ward EP, Okamuro L, Khan S, et al. - By retrospectively reviewing a prospectively maintained database, researchers intended to assess whether Ki67 could predict progression of low-grade mucinous carcinoma peritonei (LGMCP) following CRS (cytoreductive surgery)/HIPEC (hyperthermic intraperitoneal chemotherapy). They selected 44 patients with LGMCP (55% male, median age 61) who underwent complete CRS/HIPEC, with Ki67 evaluated. The median Ki67 score and hotspot Ki67 score was noted to be 15% (1–70) and 50% (1–90), respectively. Findings in this cohort revealed that disease recurrence prediction was not enabled by Ki67 in LGMCP cases analyzed herein.